Chart, page-763

Quote from https://au.finance.yahoo.com/news/why-biotron-limited-share-price-095658191.html

"This data sounds exciting, which makes the share price fall today curious, although it should be noted that the data was already public knowledge and in the market beforehand.The data is also only from a Phase 2 trial, with biotechnology companies normally having to complete three different trial phases successfully before they can apply to a healthcare regulator such as the US Food and Drug Administration (FDA) to have their treatment or therapy approved for commercial sale."

Its pretty much a waiting game with BIT, day traders will continue to manipulate the market, however investors were out because the news released wasn't new to the market and they had already knew the results from BIT225.

"Unfortunately as at September 30, 2018 the company had just $896,000 cash in hand on its balance sheet, no revenues and a cash outflow of $606,000 for the quarter.However on October 17 it reported it has raised $4.7 million via an options underwriting agreement with CPS Capital Group. It did concede though that it will still need a commercial partner to further fund more clinical trials."

If you believe in BIT hold for long term, However if you don't believe then you might as well sell and move on, count your gains or your losses